Bevacizumab: A dose review.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2015.01.012PMID 25703583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

  2023influential reference
• Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.

  2014cited by this paper
• Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.

  2014cited by this paper
• Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial

  2014cited by this paper
• Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.

  2014cited by this paper
• The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review

  2013cited by this paper
• Monitoring Monoclonal Antibody Delivery in Oncology: The Example of Bevacizumab

  2013cited by this paper
• Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).

  2013cited by this paper
• FOLFIRI plus bevacizumab (bev) as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) who have failed first-line bev plus oxaliplatin-based therapy: The randomized phase III EAGLE study.

  2013influential reference
• RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

  2013influential reference
• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

  2013influential reference
• Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

  2013cited by this paper
• Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts

  2012cited by this paper
• Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• A Phase 3 Trial of Bevacizumab in Ovarian Cancer

  2012influential reference
• AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

  2012influential reference
• A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer

  2012cited by this paper
• Normalization of the vasculature for treatment of cancer and other diseases.

  2011cited by this paper
• Treatment-Related Mortality With Bevacizumab in Cancer Patients: A Meta-analysis

  2011cited by this paper
• Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.

  2011cited by this paper
• Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer.

  2011cited by this paper
• OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells

  2011cited by this paper
• Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

  2010cited by this paper
• Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis

  2010cited by this paper
• Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.

  2010cited by this paper
• Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

  2010cited by this paper
• Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.

  2010cited by this paper
• Off-tumor target—beneficial site for antiangiogenic cancer therapy?

  2010cited by this paper
• Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

  2010cited by this paper
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010influential reference
• Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

  2009cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  2009influential reference
• Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

  2009cited by this paper
• Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

  2008cited by this paper
• Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys

  2008cited by this paper
• Clinical pharmacokinetics of bevacizumab in patients with solid tumors

  2008cited by this paper
• Paclitaxel plus bevacizumab for metastatic breast cancer.

  2008influential reference
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007influential reference
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007influential reference
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007influential reference
• Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

  2007cited by this paper
• Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

  2007cited by this paper
• Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)

  2007cited by this paper
• Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.

  2007cited by this paper
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer

  2006cited by this paper
• VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006influential reference
• Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

  2005cited by this paper
• Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics

  2005cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005influential reference
• Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects

  2005cited by this paper
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004influential reference
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects

  2003cited by this paper
• Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.

  2003cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003influential reference
• A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

  2003cited by this paper
• Role of angiogenesis in tumor growth and metastasis.

  2002cited by this paper
• Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

  2001cited by this paper
• Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001influential reference
• Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.

  1999cited by this paper
• Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies.

  1995cited by this paper

• Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.

  2025cites this paper
• Salvage Microsurgery After Failed Bevacizumab Treatment for NF2-Related Schwannomatosis Vestibular Schwannoma: A Multicentric Retrospective Study.

  2025cites this paper
• Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma

  2025cites this paper
• Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study

  2025cites this paper
• Survival in patients receiving reduced dose intensity of bevacizumab for unresectable hepatocellular carcinoma

  2025cites this paper
• Outcomes of 2-SSRS plus bevacizumab therapy strategy for brainstem metastases (BSM) over 2 cm^3: a multi-center study

  2024cites this paper
• Exploring Bevacizumab's Role in Gynecological Cancers: An Up-to-Date Narrative Review Focusing on Ovarian Cancer

  2024cites this paper
• Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles

  2024cites this paper
• Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study.

  2024cites this paper
• Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?

  2023cites this paper
• Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma

  2023cites this paper
• A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin®) in Healthy Chinese Males

  2023cites this paper
• Monoclonal antibodies and antibody-drug conjugates as emerging therapeutics for breast cancer treatment.

  2023cites this paper
• Clinically approved combination immunotherapy: Current status, limitations, and future perspective

  2022cites this paper
• The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers

  2022cites this paper
• First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

  2021cites this paper
• Efficacy of bevacizumab in the treatment of refractory brain edema of metastatic tumors from different sources

  2021cites this paper
• Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

  2021cites this paper
• In vivo SPECT-CT imaging and characterization of technetium-99m-labeled bevacizumab-loaded human serum albumin pegylated nanoparticles

  2020cites this paper
• In vivo efficacy of bevacizumab-loaded albumin nanoparticles in the treatment of colorectal cancer

  2020cites this paper
• Bevacizumab has bidirectional regulatory effects on the secretion of basic fibroblast growth factor in glioma cells.

  2020cites this paper
• Vascular Endothelial Growth Factor Blockade Induces Dermal Endothelial Cell Apoptosis in a Clinically Relevant Skin Organ Culture Model

  2020cites this paper
• Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

  2020cites this paper
• Bevacizumab and PEGylated Liposomal Doxorubicin in the Treatment of Relapsed Osteosarcoma

  2019cites this paper
• Secretogranin III as a novel target for the therapy of choroidal neovascularization

  2019cites this paper
• Function‐first ligandomics for ocular vascular research and drug target discovery

  2019cites this paper
• Antiangiogenic therapy: Markers of response, "normalization" and resistance.

  2018cites this paper
• Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma.

  2018influential citation
• The Tumor Microenvironment Regulates Retinoblastoma Cell Survival

  2018cites this paper
• Ligandomics: a paradigm shift in biological drug discovery.

  2018cites this paper
• Optimizing bevacizumab dosing in glioblastoma: less is more

  2017cites this paper
• Caractérisation au moyen d'outils mathématiques des effets vasculaires du bevacizumab à des fins d'optimisation des protocoles thérapeutiques dans le cas des tumeurs cérébrales

  2017cites this paper
• Influence of interstitial fluid dynamics on growth and therapy of angiogenic tumor. Analysis by mathematical model

  2017cites this paper
• Bevacizumab: Is the lower the better for glioblastoma patients in progression?

  2017cites this paper
• Efficacy and safety of bevacizumab treatment for refractory brain edema

  2017cites this paper
• Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients

  2017cites this paper
• Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity

  2016cites this paper
• Multiscale modeling of angiogenic tumor growth, progression, and therapy

  2016cites this paper
• Repositioning Bevacizumab: A Promising Therapeutic Strategy for Cartilage Regeneration

  2016cites this paper
• A new algorithm for a better characterization and timing of the anti-VEGF vascular effect named “normalization”

  2016cites this paper
• Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy

  2016cites this paper
• The study of antitumor e cacy of bevacizumab antiangiogenic therapy using a mathematical model

  2015cites this paper
• The study of antitumor efficacy of bevacizumab antiangiogenic therapy using a mathematical model

  2015cites this paper